跳至主要内容
临床试验/NCT01362660
NCT01362660已完成不适用

A Protocol to Monitor the Neurological Development of Infants With Exposure In-utero From Birth to Aged 15 Months in Tanezumab Clinical Studies at Investigational Sites Overseen by Schulman and Associates Institutional Review Board

Pfizer1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2011年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
7
试验地点
1
主要终点
Bayley Infant Neurodevelopmental Screener

研究概览

简要总结

This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).

详细描述

This study will enroll infants with potential tanezumab exposure in utero at sites overseen by Schulman and Associates IRB This study will attempt to enroll all infants who qualify.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
— 至 15 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical study through direct maternal exposure; or is an infant born to a mother who is a partner of a male patient who was exposed to study drug in a tanezumab clinical study prior to or around the time of conception and/or is exposed during his partner's pregnancy.

排除标准

  • There are no exclusion criteria for this study

结局指标

主要结局

Bayley Infant Neurodevelopmental Screener

时间窗: 15 months

Receptive-Expressive Emergent Language Test

时间窗: 15 months

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验